TSC Alliance Endowment Fund Partners with Aeovian Pharmaceuticals to Enhance mTORC1 Inhibitor Development The TSC Alliance Endowment Fund has invested in Aeovian Pharmaceuticals to support the new mTORC1 inhibitor aimed at treating Tuberous Sclerosis Complex, signaling a pivotal step in treatment advancements.

TSC Alliance Endowment Fund Partners with Aeovian Pharmaceuticals to Enhance mTORC1 Inhibitor Development #USA #Silver_Spring #TSC_Alliance #Aeovian_Pharmaceuticals #mTORC1_Inhibitor